A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

Introduction Transient decrease in serum prostate-specific antigen level can occur after abiraterone acetate withdrawal male patient with metastatic castration-resistant prostate cancer. Here, we report a case of syndrome transient progression to disease while using upfront therapy for high-risk Case presentation A 73-year-old man hormone-sensitive cancer multiple bone metastases (prostate-specific level, 294.109 ng/mL) received abiraterone/prednisolone combination and androgen deprivation therapy. One year later, decreased 0.017 ng/mL (nadir) but it gradually rose by 15 months treatment initiation. He was diagnosed as new appeared. After discontinued, stabilized at low 5 months. Conclusion Abiraterone observed when progressed